AU Patent

AU2020378025A1 — Crystal form of Aprocitentan, preparation method therefor and use thereof

Assigned to Crystal Pharmaceutical Suzhou Co Ltd · Expires 2022-06-23 · 4y expired

What this patent protects

Disclosed are a new crystal form of Aprocitentan (referred to as "Compound I"), a preparation method therefor, a pharmaceutical composition comprising the crystal form, and the use of the crystal form in the preparation of dual endothelin receptor antagonist drugs and dru…

USPTO Abstract

Disclosed are a new crystal form of Aprocitentan (referred to as "Compound I"), a preparation method therefor, a pharmaceutical composition comprising the crystal form, and the use of the crystal form in the preparation of dual endothelin receptor antagonist drugs and drugs for the treatment of refractory hypertension. The crystal form of Aprocitentan provided has one or more improved properties, which is of great value to the optimization and development of the drug in the future.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020378025A1
Jurisdiction
AU
Classification
—
Expires
2022-06-23
Drug substance claim
No
Drug product claim
No
Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.